Bayer AG

Explore how Bayer AG’s Supreme Court battle over glyphosate threatens its $37.7 billion market cap, stock volatility, and global reputation, and why investors must reassess its risk profile.

Discover how Bayer AG’s strategic shift—new U.S. leadership, key regulatory wins, and a 2030 pharma roadmap—positions it to deliver innovative therapies worldwide.

Investor‑driven stake sale pushes Bayer AG into focus amid new regulatory wins for Eylea 8 mg and a low‑dose MRI contrast agent, sparking a debate on whether the stock can overcome its earnings headwinds and reach the €40 ceiling.

Explore how Bayer AG’s 2026 stock performance and brand value are linked to its football club’s Bundesliga results, and discover strategies to protect investor confidence.

Explore why Bayer AG’s diverse portfolio and negative P/E ratio risk investor confidence and how strategic consolidation or risky expansion could reshape its future.

Discover how the U.S. Supreme Court’s review of Bayer’s glyphosate case is lifting the company’s stock, easing legal risks, and boosting future growth prospects.

Explore how Bayer’s 90% share‑price surge and new cost‑cut plan clash with looming glyphosate lawsuits and strategic biotech partnerships.

Discover how Bayer’s FDA approval of Hyrnuo and EU clearance of Lynkuet signal renewed growth amid litigation, reshaping investor outlook and boosting market potential.

Bayer AG reports a widening net loss for the second quarter of 2025, but sees core earnings per share increase by 30.9% and announces new initiatives to mitigate legal risks and drive growth.

Bayer AG hat trotz rechtlicher Herausforderungen in den USA seine Prognose für 2025 aufgrund der starken Nachfrage nach Medikamenten angehoben.